ArticleRespiratory research2025
Prophylactic cranial irradiation together with molecular subtyping in surgically resected small-cell lung cancer: a inverse-probability-of-treatment weighted cohort study.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundProphylactic cranial irradiation (PCI) remains a contentious therapeutic approach in small-cell lung cancer (SCLC) despite its established efficacy in reducing brain metastases. The debate persists particularly in the context of modern imaging techniques like brain MRI.
methodsThis retrospective study examined the survival outcomes associated with PCI in surgically resected SCLC patients who underwent pre-PCI brain MRI at a Chinese cancer center. A total of 309 patients were initially screened, with 110 meeting inclusion criteria after applying rigorous exclusion criteria based on a decade-long dataset. Among them, 77 patients underwent molecular subtyping based on immunohistochemistry (IHC). Clinical and pathological features, along with survival outcomes, were compared between the PCI and observation groups.
resultsAmong the final cohort, 58 patients received PCI while 52 were in the observation group. The PCI group exhibited significantly prolonged overall survival compared to the observation group (HR = 0.368, 95% CI 0.154–0.882, P = 0.0249) after adjusting for baseline imbalances using inverse probability of treatment weighting Subgroup analyses indicated notable survival benefits in male patients, those ≤ 65 years old, and individuals with pathological N0 disease. Compared to subtypes P (5.2%) and Y (11.7%), molecular subtyping indicates a higher prevalence of subtypes A (42.8%) and N (40.3%). Neuroendocrine subtypes (A and N) tend to have poorer prognoses and could obtained overall survival benefits from PCI. (HR = 0.276, 95% CI 0.091–0.839, P = 0.015).
conclusionsThis study supporting the use of PCI in surgically resected SCLC patients with pre-PCI brain MRI evaluation, demonstrating a significant survival advantage. Molecular subtyping through IHC may help identify SCLC patients who can benefit from PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.